Thales, European Leader in Quantum Physics and Artificial Intelligence, Opens InnovDays 2019
Thales launched InnovDays in 2012 as a way for its customers and partners to gain exclusive insights into the technological excellence of its research facilities. Since then, successive InnovDays events have turned the spotlight on the latest technological innovations developed by more than 29,500 Thales engineers and researchers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191127005575/en/
Thales InnovDays 2019 (Photo: Thales)
InnovDays: building a trusted future through science
InnovDays is a reflection of Thales's objective of leveraging science and high technology to build a future we can all trust. By harnessing the unprecedented precision and power of quantum physics and augmenting the performance of its systems thanks to artificial intelligence, Thales is developing the new generation of technologies that will shape the world of tomorrow.
"InnovDays is an illustration of Thales's outstanding technological capabilities and the passion displayed by our 29,500 engineers for helping our customers step up to society's major challenges through innovation." Marko Erman, Chief Technology Officer.
As an expert in critical systems, Thales is conducting in-depth research into both digital technologies and deep tech solutions to develop a portfolio of products based on a common core of technological building blocks. At InnovDays on 27, 28 and 29 November 2019, Thales will present a total of 70 practical applications of this research centred around the following themes:
Round tables:
-
Thursday 28 November:
- 8.30 am: How can we make AI trustable?
- 1.30 pm: Sovereignty in the digital age
-
Friday 29 November:
- 8.30 am: High tech and climate change: friend or foe?
- 11.00 am: The strategy and the future of air transport
- 1.30 pm: The second quantum revolution starts now!
Star guests from the world of science and industry will be taking part in these round table sessions, including Albert Fert (Nobel Prize in Physics 2007), Jean-Marc Jancovici (Founder and President of The Shift Project), Alexandre de Juniac (IATA Director General and CEO) and Pascale Senellart (research director at the Centre for Nanoscience and Nanotechnology, Paris-Saclay University, Paris-Sud University, CNRS).
Proposed press tours at InnovDays 2019
- Tomorrow's cities
- The future of transport
- Biometrics
- The Cloud
- Big Data
- Tomorrow's connectivity in the civil world
- Tomorrow's connectivity in the world of defence
- Air defence of the future
- Land and naval defence of the future
- The augmented soldier
- Secure identities and data for citizens and businesses
|
On 27, 28 and 29 November 2019, the Thales YouTube channel will feature live coverage of the round table sessions and some of the most popular demonstrations. |
From sensors that are up to 10,000 more accurate to ultra-secure communications, quantum technologies are set to push back the boundaries of physics and unleash previously unexploited properties of matter.
An aircraft flying from Paris to New York with only an inertial navigation system to guide it could determine its location to within a few kilometres. With future quantum sensors, it could land with a precision of within a metre. In other fields, quantum sensors could detect tumours that are invisible today, or provide a basis for developing new sources of energy.
Quantum physics relies on radically new concepts and ways of manipulating matter. Quantum sensors, like quantum communications and quantum computing, are currently under the microscope in the laboratories operated by Thales and its academic partners (CNRS, Université Paris-Saclay, etc.) at the Saclay research and technology cluster, south of Paris.
On 26 November 2019, Thales and its academic and research partners are organising a presentation at Saclay to highlight European excellence in quantum research: from cold atoms to flawed diamonds and superconductors, scientific progress in quantum physics has the potential to harness unexploited properties of matter and unleash a whole host of new opportunities.
Thales is working on these new properties to develop the next generation of quantum sensors, relying on the exact same technological building blocks as quantum computers. Quantum encryption too, could soon lead to communication systems that are completely secure and trustworthy.
Thales has also been selected to take part in the European OPENQKD initiative as part of the Austrian Institute of Technology (AIT) consortium chosen by the European Commission to install infrastructure in several European countries to test quantum communication networks.
Navigating intelligently among millions of aircraft movements: Thales presents the brain of tomorrow's aircraft.
Ultimately, quantum technologies will provide untold benefits for avionics systems, including order-of-magnitude improvements in navigation precision. But the immediate truth is that solutions are needed now to deal with the growth in air traffic, which is expected to have doubled by 2030.
This is the thinking behind PureFlyt, developed by Thales as the brain of tomorrow's aircraft, a fully connected cockpit that will significantly increase aircraft performance.
PureFlyt will be unveiled in Toulouse on 25 November. One of the core innovations that makes PureFlyt a game-changer is its ability to draw on both onboard and open-world data, such as weather information, so that the aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and a better flying experience for both passengers and crew.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
Thales Group
Download photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005575/en/
Contact information
PRESS
Thales, Media relations
Cédric Leurquin
+33 (0)1 57 77 90 93
cedric.leurquin@thalesgroup.com
Thales, Media relations
Alice Pruvot
+331 57 77 89 52
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
